BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Seattle - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Science in Seattle
X-ORIGINAL-URL:https://scienceinseattle.com
X-WR-CALDESC:Events for Science in Seattle
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Vancouver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210217T120000
DTEND;TZID=America/Vancouver:20210217T130000
DTSTAMP:20260718T081225
CREATED:20210208T181806Z
LAST-MODIFIED:20210208T181806Z
UID:11438-1613563200-1613566800@scienceinseattle.com
SUMMARY:Biostatistics Seminar Series
DESCRIPTION:The Fred Hutch Biostatistics Program hosts seminars featuring presentations by Hutch and outside scientists to share their latest developments and recent research. Each seminar includes an hour-long presentation and discussion during which speakers showcase their work and findings. \nThis seminar will be held on Zoom due to the COVID-19 pandemic. \nLung cancer is one of the most common cancers worldwide and the leading cause of cancer deaths both globally and in the United States. The National Lung Cancer Screening Trial showed annual screening by low-dose computed tomography (LDCT) reduced mortality and in 2013 the US Preventative Services Task Force recommended screening by LDCT for high-risk smokers. A predictive model for 6-year risk of lung cancer was developed using results of the Prostate\, Lung\, Colon\, and Ovarian Cancer Screening Trial (PLCOm2012) and put forth as selection criteria for referral to screening. The Hanash Lab at MD Anderson has established and validated a panel of four circulating protein biomarkers (4MP) for lung cancer risk assessment. In this talk\, I will describe joint work with Ziding Feng and the Hanash lab leading to a definitive validation of the 4MP using preclinical specimens from the PLCO biorepository\, highlight validation of selection criteria based on combining the 4MP with PLCOm2012\, and discuss next steps for investigating the clinical utility of a biomarker-based strategy for referral to LDCT screening.
URL:https://scienceinseattle.com/event/biostatistics-seminar-series-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210217T120000
DTEND;TZID=America/Vancouver:20210217T130000
DTSTAMP:20260718T081225
CREATED:20210208T181806Z
LAST-MODIFIED:20210208T181806Z
UID:25668-1613563200-1613566800@scienceinseattle.com
SUMMARY:Biostatistics Seminar Series
DESCRIPTION:The Fred Hutch Biostatistics Program hosts seminars featuring presentations by Hutch and outside scientists to share their latest developments and recent research. Each seminar includes an hour-long presentation and discussion during which speakers showcase their work and findings. \nThis seminar will be held on Zoom due to the COVID-19 pandemic. \nLung cancer is one of the most common cancers worldwide and the leading cause of cancer deaths both globally and in the United States. The National Lung Cancer Screening Trial showed annual screening by low-dose computed tomography (LDCT) reduced mortality and in 2013 the US Preventative Services Task Force recommended screening by LDCT for high-risk smokers. A predictive model for 6-year risk of lung cancer was developed using results of the Prostate\, Lung\, Colon\, and Ovarian Cancer Screening Trial (PLCOm2012) and put forth as selection criteria for referral to screening. The Hanash Lab at MD Anderson has established and validated a panel of four circulating protein biomarkers (4MP) for lung cancer risk assessment. In this talk\, I will describe joint work with Ziding Feng and the Hanash lab leading to a definitive validation of the 4MP using preclinical specimens from the PLCO biorepository\, highlight validation of selection criteria based on combining the 4MP with PLCOm2012\, and discuss next steps for investigating the clinical utility of a biomarker-based strategy for referral to LDCT screening.
URL:https://scienceinseattle.com/event/biostatistics-seminar-series-2-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20210217T120000
DTEND;TZID=America/Vancouver:20210217T130000
DTSTAMP:20260718T081225
CREATED:20210208T181806Z
LAST-MODIFIED:20210208T181806Z
UID:26633-1613563200-1613566800@scienceinseattle.com
SUMMARY:Biostatistics Seminar Series
DESCRIPTION:The Fred Hutch Biostatistics Program hosts seminars featuring presentations by Hutch and outside scientists to share their latest developments and recent research. Each seminar includes an hour-long presentation and discussion during which speakers showcase their work and findings. \nThis seminar will be held on Zoom due to the COVID-19 pandemic. \nLung cancer is one of the most common cancers worldwide and the leading cause of cancer deaths both globally and in the United States. The National Lung Cancer Screening Trial showed annual screening by low-dose computed tomography (LDCT) reduced mortality and in 2013 the US Preventative Services Task Force recommended screening by LDCT for high-risk smokers. A predictive model for 6-year risk of lung cancer was developed using results of the Prostate\, Lung\, Colon\, and Ovarian Cancer Screening Trial (PLCOm2012) and put forth as selection criteria for referral to screening. The Hanash Lab at MD Anderson has established and validated a panel of four circulating protein biomarkers (4MP) for lung cancer risk assessment. In this talk\, I will describe joint work with Ziding Feng and the Hanash lab leading to a definitive validation of the 4MP using preclinical specimens from the PLCO biorepository\, highlight validation of selection criteria based on combining the 4MP with PLCOm2012\, and discuss next steps for investigating the clinical utility of a biomarker-based strategy for referral to LDCT screening.
URL:https://scienceinseattle.com/event/biostatistics-seminar-series-2-3/
LOCATION:Online
END:VEVENT
END:VCALENDAR